GSK plc (LSE/NYSE: GSK) 宣布其用于治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的药物depemokimab在ANCHOR三期临床试验中取得积极成果。根据新闻稿，该试验达到了主要终点，与安慰剂加标准治疗相比，在52周内显著减少了鼻息肉大小和鼻塞程度。 Depemokimab是一种超长效生物制剂，每半年给药一次，在靶向和抑制与鼻息肉生长和阻塞相关的炎症方面显示出了前景。 GSK高级副 ...

These FTSE shares don’t have the highest yields. But Edward Sheldon believes they could deliver attractive returns in the ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

10月9日，GSK宣布就其胃灼热药物Zantac致癌问题诉讼案与10家原告公司达成和解，GSK需要为大约80000起诉讼支付22亿美元，为每位索赔人支付大约27500美元，避免其在美国面临的93%州诉讼案。

葛兰素史克(GSK.US)跌1.35%，报39.69美元。消息面上，葛兰素史克周三宣布，同意支付高达22亿美元，以解决美国州法院提起的大多数诉讼，这些诉讼指控一种已停产的胃灼热药物Zantac会导致癌症。该公司与10家原告律师事务所达成的协议解决了约 ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

British pharmaceutical company GSK has agreed to pay $2.3 billion to settle lawsuits alleging that its heart burn medication Zantac caused cancer. GSK has settled 80,000 Zantac lawsuit. Watch to know ...

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...

GSK to resolve 93% of US state court Zantac product liability cases for up to $2.2 billion: London, UK Friday, October 11, 2024, 14:00 Hrs [IST] GSK plc announced that it has reac ...

葛兰素史克欧股涨6%，此前宣布将支付22亿美元和解其产品Zantac产品致癌问题引发的诉讼。